News - BridgeBio
Jun 10, 2024 · Catch up on news from BridgeBio and our pipeline developments. Follow us on LinkedIn, Twitter, and Facebook to keep up with all of the latest news.
FDA Acceptance of New Drug for Infigratinib | BridgeBio
Dec 1, 2020 · BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma. Application …
BridgeBio Announces Progress in Many Areas | BridgeBio
Oct 12, 2021 · BridgeBio will announce BridgeBioX, the company’s new early research discovery engine with a dedicated lab at Stanford University. BridgeBio created BridgeBioX to test earlier …
Fourth Quarter and Full Year 2021 Financial Results | BridgeBio
Feb 24, 2022 · BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update –Secured up to $750 million in non-dilutive debt financing in November …
Second Quarter 2022 Financial Results | BridgeBio
Aug 4, 2022 · BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update – Reported positive interim Phase 2 data for infigratinib in achondroplasia …
BridgeBio Completes Merger with Eidos | BridgeBio
Jan 26, 2021 · BridgeBio announced that it has completed its acquisition of all of the outstanding shares of Eidos common stock that BridgeBio did not already own.
Press Releases - BridgeBio Pharma
Sep 27, 2024 · BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb …
BridgeBio Pharma Announces $250 Million Private Placement …
Sep 25, 2023 · BridgeBio anticipates the gross proceeds from the PIPE financing to be approximately $250 million, before deducting offering expenses. The PIPE financing is …
BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 …
PALO ALTO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused …
FDA Approval of TRUSELTIQ™ | BridgeBio
May 28, 2021 · BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma …